TABLE 2.
Differences between MCI and NL in CSF biomarkers value across different studies.
| First author, year | MCI (n) |
NL (n) |
MCI values as a percentage of NL | ||
|---|---|---|---|---|---|
| Aß42 | T-tau | P-tau | |||
| Bouwman 2007[96] | 38 | 17 | 70.3% | 178.1% | 137.7% (181) |
| Brys 2009[28,99] | 65 | 21 | 162.9% | 187.3% (231) | |
| Buerger 2005[224] | 59 | 28 | 172.5% (181); 199.2% (199); 864.2% (231) |
||
| Buerger 2009[197] | 17 | 15 | 77.7% | 124.1% | 118.0% (181); 375.0% (231) |
| de Leon 2002[225] | 8 | 10 | 40% | 234% (231) | |
| Fellgiebel 2008[199] | 10 | 10 | 194.2% (181) | ||
| Hansson 2006[226] | 134 | 39 | 66.2% | 175.0% | 125.4% (181) |
| Kester 2011[100] | 62 | 24 | 76.2% | 149.0% | 135.5% (181) |
| Lavados 2005[227] | 37 | 18 | 110.9% | ||
| Maccioni 2006[210] | 45 | 25 | 85.7% | 111.6% (AD epitopes) | |
| Maruyama 2001[211] | 19 | 15 | 95.8% | 290.8% | |
| Mattsson 2009[193] | 750 | 304 | 69.2% | 135.7% | 119.6% (181) |
| Okonkwo 2011[213] | 195 | 114 | 79.4% | 148.7% | 143.6% (181) |
| Pratico 2002[228] | 17 | 18 | 129.7% | ||
| Rolstad 2011[215] | 170 | 60 | 78.8% | 128.1% | |
| Schonknecht 2007[229] | 80 | 24 | 175.9% | 134.6% (181) | |
| Seppala 2011[217] | 57 | 8 | 103.2% | 92.5% | 101.7% (181) |
| Shaw 2009[128] | 196 | 114 | 79.6% | 147.1% | 144.0% (181) |
| Visser 2009[131] | 108 | 89 | 74.5% | 149.6% | 147.6% (181) |
Values are given as percentage of value for the control healthy group. For p-tau the numbers in parentheses indicate phosphorylation site studied. Across all studies listed in this table Aß42 concentration in the MCI group was 77% of that in NL group (13 studies),average p-tau181 concentration was 140% of NL group value (11 studies), p-tau231 was 357% (4 studies), and t-tau 153% (15 studies).